INTRODUCTION
Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder affecting up to 20% of the population (1), in which patients report abdominal pain or discomfort associated with disordered defaecation or change in bowel habit. Patients can present with either constipation (IBS-C) and diarrhea (IBS-D) or a mixture of both (IBS-M).
Notably, women are twice as likely to be affected as men (2) and a high proportion of IBS patients are reported to show comorbidity with psychiatric conditions like anxiety or depression (3, 4) . The disorder accounts for nearly half of gastroenterology clinic referrals, markedly reduces quality of life and treatment remains far from satisfactory. The lack of adequate treatment and the unsuccessful development of new drugs stem from poor understanding of its pathophysiology. Nevertheless, there is evidence of an altered GI motility, with some studies reporting slow GI transit, reduced motility and incidence of high amplitude propagating contractions in IBS-C (5). In IBS-D, accelerated transit, increased motility and high amplitude propagating contractions were described (6) . Other studies have suggested that approximately two-thirds of IBS patients may also be more viscerally sensitive to intra-luminal events such as distension than healthy subjects, with slightly more patients with IBS-D being affected than IBS-C (7). Why some but not all patients exhibit this phenomenon remains unknown, but evidence is emerging of a possible genetic link to these phenotypic variations. Family studies provide strong evidence for a clustering of functional bowel disorders in families. Furthermore, twin studies clearly demonstrate an increased concordance rate in monozygotic compared to dizygotic twins. Thus, hereditary factors are likely to be involved in the etiology of IBS (8 -10) , with recent studies estimating this to be 50% in females (11) .
The 5-HT 3 receptor is a Cys-loop ligand-gated ion channel composed of five subunits (12) . It is an important mediator of the action of 5-HT, and has been shown to play a key role in the motor-sensory function of the gut (13) . In the GI tract, 5-HT 3 receptors are located on peripheral nerve terminals of both vagal and spinal primary afferent neurons innervating the gut, as well as on myenteric and submucosal neurons. They have also been described in the spinal cord and throughout the brain, mostly in the limbic and cortical regions. Importantly, the 5-HT 3 receptor antagonist alosetron is effective in the management of IBS-D, with this being attributed to its suppressing effects on motility and secretion by its action on receptors probably located within the GI tract, and its effect on abdominal pain by maybe its interaction with receptors in the spinal cord and/or the brain. However, not all patients respond to this agent, particularly males, which might be explained by the genetic variability of 5-HT 3 receptor genes.
To date, five human 5-HT 3 receptor subunit genes have been isolated: HTR3A, HTR3B, HTR3C, HTR3D and HTR3E (14 -16). The 5-HT 3A subunit seems to have a key function in the formation of 5-HT 3 receptors since it is the only subunit that can form functional homopentamers. In contrast, all other subunits form functional heteromers when co-expressed with the 5-HT 3A subunit (15, 17) . Expression analyses of all five subunit genes have revealed that the 5-HT 3E subunit is exclusively expressed in GI tissues-like colon, small intestine and stomach, whereas the other subunits are more ubiquitously expressed (16, 18) . This indicates that the 5-HT 3E subunit may play a distinct and specific role in the formation and function of 5-HT 3 receptors in the human GI tract.
Genetic variations that alter gene expression cause phenotypic diversity and play an important role in disease susceptibility especially with regard to complex conditions (19) . As evidence accumulates that cis-regulatory variants in the untranslated regions (UTRs) of genes may have a significant impact on gene expression (20, 21) , the aim of this study was to investigate whether variants in the UTRs of the 5-HT 3 receptor genes HTR3A and HTR3E may be predisposing or contributing to the clinical signs of IBS with diarrhea.
RESULTS

Sequence variants HTR3E c.
Ã 76G>A and HTR3A c.-42C>T are associated with IBS-D
We analyzed the 5 0 -and 3 0 -UTR of HTR3A and HTR3E in DNA samples of 100 IBS-D, 100 IBS-C patients and 100 healthy controls in a pilot cohort from the UK. Using dHPLC and direct sequencing of the generated PCR products, four sequence variants for HTR3A were identified. Two of these were located in the 5 0 -UTR (c. Table S1 ). Statistical analyses on the genotype frequencies obtained for the identified variants of both genes were performed to determine whether there are significant differences between the two IBS subgroups and healthy controls. We found the novel HTR3E variant c.
Ã 76G.A (rs62625044) and the HTR3A variant c.-42C.T (rs1062613) associated with the IBS-D phenotype of the disease.
The heterozygous genotype of the HTR3E c. Ã 76G.A variant was more frequent in female IBS-D patients compared to female healthy controls [P ¼ 0.033, odds ratio (OR)¼8.53, 95% CI ¼ 1.04 -70.28] or female IBS-C patients (P ¼ 0.125, OR ¼ 3.03, 95% CI ¼ 0.88 -10.52) or compared to the pooled group of non IBS-D females (P ¼ 0.010, OR ¼ 4.13, 95% CI ¼ 1.30-13.14), whereas there were no genotype frequency differences between female IBS-C patients and female healthy controls (Table 1 ). There were no significant differences between male IBS patients and healthy males or between patients of both sexes compared to controls of both sexes (Supplementary Material, (Fig. 1A) . The calculated score of 19.12 (22) for putative binding of miR-510 was the highest of 41 predicted miRNAs with calculated scores in the range of 13.94 -19.12. To confirm a putative HTR3E -miR-510 interaction, we co-transfected the 3 0 -UTR c. Ã 76G luciferase construct with different concentrations of miR-510 precursor molecules or same amounts of negative control miRNA with a random sequence (Ambion). Higher concentrations of miR-510 (40 or 100 nM, but not 4 nM) led to a significant reduction of luciferase activity to 55-60% compared to negative control miRNA (100%; P , 0.001) (Fig. 1B) . These findings confirm the predicted binding of miR-510 to the 3 0 -UTR of HTR3E and demonstrate a dose-dependent reduction of reporter gene expression. Since the binding site for miR-510 includes the sequence variant c.
Ã 76G.A, we next investigated if the presence of the c.
Ã 76A variant allele interferes with the ability of miR-510 to interact with the 3 0 -UTR of HTR3E. We co-transfected the HTR3E 3 0 -UTR c.
Ã 76G and c. Ã 76A luciferase constructs with 40 nM of miR-510, negative control miRNA or anti-miR-510 precursor molecules into Colo320 and HEK293 cells. The anti-miR-510 precursor molecules are single-stranded RNA molecules which specifically knock-down endogenous miR-510. As predicted, the c.
Ã 76A variant constructs co-transfected with miR-510 showed significantly higher (180%) luciferase expression compared to c.
Ã 76G allele constructs (100%; P , 0.001) in HEK293 cells, which do not endogenously express the 5-HT 3E receptor subunit (Fig. 2B) . We confirmed these findings in 5-HT 3E expressing Colo320 cells (Fig. 2C) . In both cell lines, no significant luciferase activity differences exist when co-transfecting negative control or anti-miR-510 precursor molecules. 
Values indicate number of patients and healthy controls with the respective genotype. Odds ratios (OR), 95% confidence intervals (CI) and P-values calculated using the Fisher's exact test (P F ) or the x 2 test (P x ) in a minor allele dominant model. Frequencies (in%) were rounded up or down to the nearest whole number. UK, United Kingdom. 
The c.
Ã 76G>A variant does not affect HTR3E mRNA levels in Colo320 cells
We performed quantitative real-time PCR to assess mRNA levels of HTR3E in Colo320 cells transfected with the pcDNA3 HTR3E-Myc-3 0 -UTR c. Ã 76G or c. Ã 76A construct in combination with miR-510 or negative control miRNA precursor molecules. No differences in the HTR3E mRNA levels (normalized to neomycin transferase mRNA levels) were detectable for any combination of transfected constructs (Supplementary Material, Fig. S1 ). This indicates that the binding of miR-510 to the HTR3E mRNA does not seem to affect mRNA transcription levels or mRNA stability, but decreases gene expression at the translational level.
HTR3A, HTR3E and miR-510 are co-expressed in enterocytes and myenteric plexuses of the human colonic mucosa
To further investigate the interaction of miR-510 and HTR3E seen by in vitro analyses, we performed in situ hybridization on human colon tissue sections to check for overlapping expression of these two genes and, in addition, also for HTR3A expression. We found all three genes to be co-expressed specifically in enterocytes of the colonic mucosa ( Fig. 3 ) as well as in myenteric plexuses (not shown). The co-expression of 5-HT 3A and 5-HT 3E in the respective cells was confirmed by immunofluorescence experiments using specific antibodies (Fig. 3) . These results indicate that the expression of the 5-HT 3E subunit in vivo can be controlled by the co-expressed miR-510 and that 5-HT 3 receptors located in the investigated region comprise 5-HT 3A and 5-HT 3E subunits.
Confirmation of HTR3E and miR-510 co-expression in enterocytes of the colonic mucosa by RT -PCR
Microdissected tissue of the epithelial layer of human colonic mucosa was analyzed by RT -PCR. We found HTR3E and miR-510 both expressed in enterocytes, whereas no expression of HTR3E and only low expression of miR-510 were detectable within the lamina propria (Fig. 4) . (Fig. 5B) , whereas radioligand affinity remained unchanged (data not shown). These findings confirm our previous results and furthermore implicate that the c.-42C.T variant results in elevated expression levels of 5-HT 3A subunits, which can be interpreted as a higher homomeric receptor density on the cell surface.
DISCUSSION
This study has identified the functional HTR3E c.
Ã 76G.A variant to be associated with the diarrhea phenotype of IBS in females and delivered first evidence for a microRNA regulated expression of 5-HT 3 receptor genes. The variant showed highly significant association with female IBS-D in two independent cohorts from the UK and Germany. This underlines the possible impact of c.
Ã 76G.A in the etiology of female IBS-D while the relevance of the HTR3A c.-42C.T variant remains questionable as it failed replication in the German patients. In vitro studies showed that both variants lead to an increased expression of the 5-HT 3A and 5-HT 3E subunits at the translational level by affecting cis-regulatory mechanisms.
Luciferase assays revealed that the presence of a miR-510 binding site in the 3 0 -UTR of HTR3E significantly reduces expression of the luciferase carrying the c.
Ã 76G allele 3 0 -UTR. This confirmed the predicted functional interaction of miR-510 with the HTR3E mRNA and indicates regulation of 5-HT 3E subunit expression by miR-510 in vivo. MiRNAs typically bind to the 3 0 -UTR of their targets and repress translation. It is hypothesized that regulation by miRNAs is responsible for adjustment of gene dosage within the cell. It is currently estimated that miRNAs account for 1% of predicted genes in higher eukaryotic genomes and that up to 30% of genes might be regulated by miRNAs. However, only very few miRNAs have been functionally characterized in detail (24, 25) . Recently, SNPs residing in miRNA-binding sites were shown to affect the expression of miRNA targets and contribute to the susceptibility to complex disorders such as cancer, asthma, cardiovascular disease and Tourette syndrome (26 -30) . In the present study, the c.
Ã 76G.A variant diminishes the ability of miR-510 to bind to the 3 0 -UTR of HTR3E, thereby protecting the mRNA from translational repression. As HTR3E is exclusively expressed in the GI tract, the upregulation of gene expression caused by c.
Ã 76G.A may specifically affect 5-HT 3 receptors in the digestive system of variant carriers. Increased 5-HT 3E subunit expression might cause changes in receptor composition or lead to higher receptor density in the cell membrane as seen in vitro for homomeric 5-HT 3A receptors carrying the c.-42C.T variant.
Interestingly, we found the strongest association of the HTR3E variant c.
Ã 76G.A with IBS-D in female patients. Gender-related differences in IBS prevalence (two thirds of patients are female) and in response to pharmacological treatment are described, yet poorly understood. Our findings indicate that female c.
Ã 76G.A variant carriers have a much higher risk for developing IBS-D than male carriers. Further studies are needed to clarify why the c.
Ã 76G.A variant seems to have this gender specific effect. This could be related to the fact that gonadal hormones influence GI motility and sensory afferent pathways and central processing of visceral stimuli (31) .
By in situ hybridization and immunofluorescence experiments, we found HTR3A, HTR3E and miR-510 co-expressed in enterocytes and myenteric plexuses of human colon sections. The co-expression of HTR3E and miR-510 in enterocytes was confirmed by RT -PCR of microdissected tissue. These findings suggest that native 5-HT 3 receptors in colonic enterocytes are comprised of 5-HT 3A and 5-HT 3E subunits and that the expression of the latter is regulated by the co-expressed miR-510. This is, to our knowledge, the first study describing the presence of 5-HT 3 receptors in colonic enterocytes, suggesting that 5-HT 3 receptors are involved in human mucosal secretion stimulated by serotonin. This remains controversial, as a recent study suggested no involvement of 5-HT 3 receptors in secretion, at least in human duodenum (32) . Further analyses of human GI tract tissue samples using different 5-HT 3 agonists and antagonists are needed to elucidate a potential involvement of 5-HT 3 receptors in the regulation of mucosal secretion.
In a previous study, the c.-42C.T variant was shown to be located in an upstream open reading frame (uORF) of HTR3A resulting in an amino acid exchange (Pro16Ser) in the predicted upstream peptide (23) . Peptides encoded by uORFs are thought to participate in the regulation of gene expression by blocking the scanning ribosome during the elongation phase and by diminishing translation of the downstream gene (33) . We have now demonstrated that the c.-42C.T variant leads to higher 5-HT 3A receptor density in the membranes of transfected HEK293 cells. The 5-HT 3A subunit Figure 4 . Confirmation of HTR3E and miR-510 co-expression in enterocytes of the human colonic mucosa by RT -PCR. Microdissected tissue of the mucosal cell layer of the epithelium of human colon was analyzed by RT-PCR. HTR3E expression is restricted to the enterocytes (E). No HTR3E expression is detectable within the lamina propria (LP). For miRNA-510, a strong expression is detected in enterocytes and a weak expression within the lamina propria (LP). neg., negative control.
seems to play a crucial role in receptor formation, as it is the only 5-HT 3 subunit that can form functional homopentameric receptors in vitro. In addition, heteromeric assemblies of 5-HT 3AB, AC, AD, and AE form functional receptors (17) . It is, therefore, possible that the presence of the c.-42C.T variant might affect composition and density of native 5-HT 3 receptors in various human tissues. Patients suffering from IBS frequently show comorbidity with anxiety and depression (3, 4) . Previous studies have found c.-42C.T to also be associated with bipolar affective disorder, harm avoidance in women and modulation of amygdaloid activity (23, 34, 35) . Therefore, elevated expression levels of the 5-HT 3A subunit caused by the c.-42C.T variant may contribute to both, dysfunction of brain and gut-related serotonin signaling mediated by 5-HT 3 receptors. As the association of the c.-42C.T variant failed replication in the German IBS-D and controls cohort, its impact in the etiology of IBS-D remains unclear yet associations to psychiatric traits cannot be excluded and further studies are necessary to evaluate the role of this variant in IBS-D.
Depending on the localization and receptor composition, the functions of 5-HT 3 receptors within the GI tract and CNS are many and diverse. 5-HT 3 receptors are located on the intrinsic and extrinsic neural pathways, spinal and CNS neurons and, as shown in the present study, on mucosal enterocytes. In the gut, they are thought to be involved in motor-sensory function and secretion (36, 37) . Thus, it is possible that the increased 5-HT 3A and 5-HT 3E subunit expression might lead to an increased density of 5-HT 3 receptors or alter the receptor composition and cause hypercontractility and secretion along with visceral hypersensitivity, features typical of IBS-D. Our hypothesis is supported by the fact that 5-HT 3 receptor antagonists-like alosetron and ondansetron seem to directly influence these processes. They have been shown to slow small and large bowel transit, inhibit small bowel secretion, decrease colonic compliance and inhibit the colonic response to feeding (37) . Moreover, although their effects on basal sensitivity to balloon distension are inconsistent (37), they do appear to reduce colonic hypersensitivity induced by duodenal lipid infusion (38) and decrease activity and activation in response to rectal balloon distension in the emotional motor system of the CNS (39, 40) . Both compounds have been shown to improve symptoms and the bowel habit of, in particular, female patients with IBS-D (37, 41) .
In conclusion, our data represent an important step in understanding the complex mechanisms of 5-HT 3 receptor expression regulation. We found cis-regulatory mechanisms to fine-tune expression of the receptor subunits 5-HT 3A and 5-HT 3E by translational repression. Two functional variants residing within these crucial regulatory elements have been identified with both resulting in increased expression of the respective subunit. The HTR3E c.
Ã 76G.A variant seems to 
MATERIALS AND METHODS
IBS patients and healthy controls from the UK
The HTR3E mutation analysis was carried out on a pilot cohort of 100 patients with IBS-D (aged 18-66 years; mean age 41.5 years; 32 male), 100 IBS-C patients (aged 18 -65 years; mean age 40.5 years; 5 male) and 100 healthy controls (aged 18-63 years; mean age 35.3 years; 35 male). For the HTR3A mutational analysis, 98 IBS-D patients (aged 18-66; mean age 41.7 years; 31 male) and 99 IBS-C patients (aged 18-65 years; mean age 40.6 years; 5 male) of the same patient pools and the 100 healthy controls were screened. IBS patients with a mixed bowel habit (IBS-M) were excluded from the study. IBS patients were recruited from the Out Patients Departments of the University Hospitals of South Manchester (tertiary patients excluded), local general practices, advertisement in regional news papers and an existing departmental volunteer pool of patients. All satisfied the Rome II criteria for IBS and predominant bowel habit subtype (42) . All patients underwent appropriate investigations to exclude organic disease (1) and did not show any functional disorder of the upper GI tract that was more prominent than their IBS. In addition, no subject had a history of major psychiatric disorder or history of alcohol or substance abuse. Healthy controls were recruited by advertisement. All subjects were Caucasian and drank below the recommended safe alcohol limit (,21 units/week), smoked ,5 cigarettes per day and had not participated in a clinical trial of any drug within the previous 30 days. Written consent was obtained from all subjects and the study was approved by the South Manchester Medical Research Ethics Committee.
German IBS-D patients and healthy controls
For the replication study, we investigated 119 unrelated IBS-D patients (aged 19-79; mean age 44.6 years; 44 male) recruited from the outpatient clinic of the medical department at Charité University Medical Center, Campus Virchow-Klinikum, Berlin. The patients satisfied the Rome III criteria for IBS-D and the presence of other diseases that could explain symptoms was excluded by appropriate investigations. Immunology (Mannheim, Germany). According to the German guidelines for blood donation, all blood donors were examined by a standard questionnaire. All blood donors consented to the use of their samples for research studies. The study was approved by the Ethics Committee of the University of Heidelberg (Heidelberg, Germany).
Preparation of genomic DNA
Genomic DNA was prepared from blood samples taken from both the patients and healthy controls using standard protocols (43) .
Polymerase chain reaction
PCRs were performed in 25 ml volumes containing 50 ng of genomic DNA as template, 
dHPLC analysis
Prior to direct sequencing, the WAVE DNA fragment analysis system was used as a tool for fast and sensitive detection of unknown sequence variants according to conditions recommended by the manufacturer (Transgenomic). The formation of heteroduplexes was achieved by denaturing the PCR products at 958C for 5 min and gradually cooling them down to 48C in 45 cycles (228C per cycle). A 5 ml aliquot of PCR product was loaded on the DNASep column (Transgenomic). Gradient parameters and column temperatures for each amplicon were calculated using the software supplied with the WAVE system. Each amplicon was analyzed at two different column temperatures (Supplementary Material, Table S2 ). In case of detection of a putative sequence variant within an amplicon, all samples were subject to direct sequencing of the respective amplicon to assure detection of homozygous variants which are not detectable by using dHPLC.
Purification and direct sequencing of PCR products A 5 ml aliquot of PCR product was treated with 2 U shrimp alkaline phosphatase (SAP) and 5 U exonuclease I (ExoI; MBI Fermentas) for 15 min at 378C followed by inactivation at 808C for 15 min. Two microliter of the ExoI/SAP-treated PCR product was used for direct sequencing using the DYEnamic ET Terminator Cycle Sequencing Kit according to the manufacturer's protocol (GE Healthcare). The MegaBACE 1000 sequencer and the software provided by the manufacturer (GE Healthcare) were used for the analysis of the sequence reaction products.
Expression and luciferase reporter constructs
The pcDNA3 HTR3A-5 0 -UTR c.-42C and c.-42T constructs (Fig. 5A) were constructed by cloning the respective 5 0 -UTR upstream of an existing pcDNA3 HTR3A cDNA construct. To create the pRL-TK HTR3E-3 0 -UTR c. Ã 76G and c. Ã 76A renilla luciferase reporter constructs ( Fig. 2A) , the respective full-length HTR3E 3 0 -UTR fragments were amplified from genomic DNA using forward primer 5 0 -ATTATCTAGAGCA GGTGCTCACCTGCCAAC-3 0 and reverse primer 5 0 -ATTAT CTAGACTGCAGAATTATTTATTGGG-3 0 (both with an XbaI tail). The XbaI-digested PCR products were ligated into the XbaI site of the pRL-TK renilla luciferase vector (Promega). Constructs were purified using the PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen) and integrity of insert sequence and orientation was verified by sequencing using the MegaBACE system (GE Healthcare).
Cell culture and transfection
HEK293 and Colo320 cells were maintained in DMEM supplemented with 10% FBS, 100 U/ml penicillin G sodium and 100 mg/ml streptomycin sulfate. For luciferase assays, the cells were splitted into 24-well plates at approximately 5.0 Â 10 5 cells per well prior to transfection. Cells were transiently transfected using 4 mg of polyethylenimine (Sigma-Aldrich) per 1 mg of construct DNA and cells were harvested 24 h after transfection. For radioligand binding assays, HEK293 cells were splitted into 75 cm 2 cell culture flasks and transfected by TransITw-293 (Mobitec). The assay was performed 48 h after transfection.
Luciferase assay
Four hundred nanograms (per well) of renilla luciferase reporter construct (pRL-TK HTR3E 3 0 -UTR c. Ã 76G/c. Ã 76A) and 100 ng (per well) of reference construct pGL3-Control (firefly luciferase; Promega) were co-transfected in the presence of 4, 40 or 100 nM of hsa-miR-510 pre-miR precursor molecules or pre-miR negative control no. 1 or hsa-miR-510 anti-miR miRNA inhibitor (Ambion). The luciferase assay was performed using the dual-luciferase reporter assay system (Promega) and a Lucy2 luminometer (Rosys Anthos Mikrosysteme) according to the manufacturer's protocols. A 25 ml aliquot of cell-lysate was used per luciferase activity measurement. Three replicates were performed for each transfection and luciferase activity was measured 3-fold.
Membrane preparation and radioligand binding assay
Radioligand binding with the 5-HT 3 receptor ligand [ 3 H]GR65630 (86 Ci/mmol; PerkinElmer) was carried out on membranes of HEK293 cells transfected with either the pcDNA3 HTR3A-5 0 -UTR c.-42C or the c.-42T construct as described previously (17) .
Preparation of tissue sections and in situ hybridization
Six unaffected, normal colon tissue samples from four female and one male patient (55 -78 years old; three colonic cancer patients and two patients with diverticulitis) were used for cryosections. Frozen tissue sections (12 mm) were fixed in 1Â PBS containing 4% paraformaldehyde for 20 min and then washed twice in 1Â PBS for 10 min each. The sections were dehydrated and stored at -808C. Prior to hybridization, the sections were thawed and rehydrated. The HTR3A-and HTR3E-specific hybridization probes were synthesized from 3 0 -UTR cDNA fragments, subcloned into the pSTBlue-1 vector (Novagen), using the MAXIscript in vitro transcription kit (Ambion). Sense and antisense probes were generated using T7 or Sp6 polymerase. The probes were labeled with digoxigenin (DIG) by adding DIG RNA Labeling Mix (Roche) and purified using NucAway spin columns (Ambion) according to the manufacturer's protocols. For detection of miRNA-510 expression, a specific 5 0 DIG-labeled antisense-locked nucleic acid (LNA) oligonucleotide (Exiqon) was used. The 5 0 DIGlabeled scramble-miRNA (negative control) was purchased from the same company. MiRNA in situ hybridizations were performed according to a protocol recommended by Exiqon at a hybridization temperature of 568C. The HTR3A-and HTR3E-specific probes were hybridized at 688C using a modification of a previously published protocol (44) .
Immunofluorescence
For localization of 5-HT 3A and 5-HT 3E subunits in human colon tissue sections, immunofluorescence experiments were carried out as follows: tissue sections (8 mm) were fixed by incubation in 4% paraformaldehyde for 20 min. Afterwards, they were washed three times for 10 min in 1Â PBS at room temperature. Then slides were blocked in 4% goat serum/0.25% Triton-X-100/PBS. The primary antibodies rabbit anti-5-HT 3A or anti-5-HT 3DE were diluted 1:100 in blocking solution and applied over night at room temperature. Afterwards, tissue sections were washed 3 Â 10 min in 1Â PBS at room temperature and incubated in blocking solution containing the Alexa Fluor 488-labelled (Invitrogen) secondary antibody goat anti-rabbit for 3 h. From then on, every step was carried out light protected. After washing for three times for 5 min in 1Â PBS, a nuclear counterstain with 4 0 ,6-Diamidino-2-phenylindol (DAPI, 1:10.000 in 1Â PBS) was carried out followed by two washes in 1Â PBS. Sections were mounted in Vectashield (Vector) and stored at 48C until microscopical investigation by a Zeiss Axiophot.
Laser microdissection and pressure catapulting
Fresh frozen colon mucosa samples were cut into 18 mm thick sections using a cryostat (Leica CM1850, Leica Microsystems) and processed as following: the sections were mounted on membrane slides (PEN-membrane, 1 mm glass, Carl Zeiss MicroImaging GmbH) and incubated for 10 min at 2208C in RNAlaterw-ICE (Ambion). For further preservation, samples were fixed in ethanol and stained in cresyl violet acetate (1% (w/v) in ACS-grade ethanol, Sigma-Aldrich) for 15 s. Subsequently, the slides were washed in ethanol and incubated for 5 min in xylene. After air-drying, the slides were mounted on the stage of an inverse microscope which is a component of a Microbeam LMPC System (Carl Zeiss MicroImaging GmbH). We employed the RoboLPC method to microdissect and capture the appropriate tissue fragments (approx. 10 mm 2 epithelium, 100 000 -250 000 cells). For sample collection, we applied 0.5 ml AdhesiveCapsw opaque (Carl Zeiss MicroImaging GmbH).
RNA isolation and RT -PCR of microdissected samples
Total RNA was isolated from each sample using the Chomczynski/Sacchi (45) method according to the manufacturer's instructions (peqGOLD TriFast TM kit, PeqLab Biotechnologie GmbH). For precipitation 2 ml of Pellet Paintw Co-Precipitant (Novagen) per sample was used. After DNAse treatment (DNA-free TM , Ambion), 200 ng of RNA was reverse transcribed using the Accuscriptw High Fidelity first strand cDNA synthesis kit (Stratagene). PCR was performed using HotStarTaq DNA Polymerase (Qiagen) according to the manufacturer's protocol. Primers are given in Supplementary Material, Table S5 .
Statistics
Comparison of genotype frequencies, association analyses and test for deviation from the HWE were performed using an online tool provided by the Institute of Human Genetics in Munich (http://ihg.gsf.de/cgi-bin/hw/hwa1.pl) and the SAS v9.1 software (SAS Institute Inc.). For the association analyses, the frequencies of genotypes were compared in a minor allele dominant model using a 2 Â 2 contingency table. We calculated P-values using the x 2 test. In those cases where the expected value of at least one cell of the contingency table was below 5, we used the Fisher's exact test. Corrections for multiple testing were performed as indicated in the results. For sample power calculations, we used Quanto 1.2 (http://hydra.usc.edu/gxe). For the luciferase and radioligand binding assay results, the independent samples t-test was performed using the MedCalc software (http:// www.medcalc.be).
In silico analysis of microRNA binding sites
We performed in silico analysis of micro-RNA binding sites, using the miRBase Target database, release 8.2 (http://microrna.sanger.ac.uk) (22) .
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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